ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · EFO_1001466

Graves ophthalmopathy

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. Graves ophthalmopathy. Diseases, record EFO_1001466. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001466

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
Graves ophthalmopathy
Open Targets
Open Targets ID
EFO_1001466
Open Targets
Other names
Congestive Ophthalmopathy, Dysthyroid Ophthalmopathy, Edematous Ophthalmopathy, Graves' orbitopathy, Myopathic Ophthalmopathy, Thyroid-Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy, dysthyroid/thyroid-associated orbitopathy (TAO), thyroid eye disease (TED)
Open Targets
MeSH
D049970
MeSH
Highest stage of its drugs
Approval, for 1 of its 30 drugs, from DailyMed, EMA Human Drugs and FDA
Open Targets

Drugs30

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
TEPROTUMUMABCHEMBL1743079AntibodyApprovalDailyMed, EMA Human Drugs and FDA1177Drugs and targets
METHYLPREDNISOLONECHEMBL650Small moleculePhase 3ClinicalTrials.gov141413Drugs and targets
BATOCLIMABCHEMBL4650514AntibodyPhase 3ClinicalTrials.gov555Drugs and targets
TOCILIZUMABCHEMBL1237022AntibodyPhase 3ClinicalTrials.gov444Drugs and targets
ATORVASTATINCHEMBL1487Small moleculePhase 3ClinicalTrials.gov222Drugs and targets
EFGARTIGIMOD ALFACHEMBL4297551ProteinPhase 3ClinicalTrials.gov222Drugs and targets
PREDNISONECHEMBL635Small moleculePhase 3ClinicalTrials.gov221Drugs and targets
SATRALIZUMABCHEMBL3833307AntibodyPhase 3ClinicalTrials.gov222Drugs and targets
METHIMAZOLECHEMBL1515Small moleculePhase 3ClinicalTrials.gov111Drugs and targets
PREDNISOLONECHEMBL131Small moleculePhase 3ClinicalTrials.gov110Drugs and targets

1 to 10 of 30

See all 30 drugs

Targets72

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
NR3C1Glucocorticoid receptor3Glucocorticoid receptor agonistPhase 3https://conductscience.org/library/genes/2908Drugs and targets
FCGRTIgG receptor FcRn large subunit p512IgG receptor FcRn large subunit p51 antagonist; IgG receptor FcRn large subunit p51 inhibitorPhase 3https://conductscience.org/library/genes/2217Drugs and targets
HMGCR3-hydroxy-3-methylglutaryl-coenzyme A reductase2HMG-CoA reductase inhibitorPhase 3https://conductscience.org/library/genes/3156Drugs and targets
IGF1RInsulin-like growth factor 1 receptor2Insulin-like growth factor I receptor antagonistApprovalhttps://conductscience.org/library/genes/3480Drugs and targets
IL17AInterleukin-17A2Interleukin 17A inhibitorPhase 3https://conductscience.org/library/genes/3605Drugs and targets
IL6RIL6Ralpha/GP1302IL6Ralpha/GP130 antagonist; Interleukin-6 receptor alpha subunit inhibitorPhase 3https://conductscience.org/library/genes/3570Drugs and targets
MMP1Interstitial collagenase2Matrix metalloproteinase-1 inhibitorPhase 2/3https://conductscience.org/library/genes/4312Drugs and targets
MMP13Collagenase 32Matrix metalloproteinase 13 inhibitorPhase 2/3https://conductscience.org/library/genes/4322Drugs and targets
MMP7Matrilysin2Matrix metalloproteinase 7 inhibitorPhase 2/3https://conductscience.org/library/genes/4316Drugs and targets
MMP8Neutrophil collagenase2Matrix metalloproteinase 8 inhibitorPhase 2/3https://conductscience.org/library/genes/4317Drugs and targets

1 to 10 of 72

See all 72 targets

Trials52

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT01868997Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye DiseasePhase 2882017-08-30Thyroid Associated Ophthalmopathies, Thyroid-Associated OphthalmopathyTEPROTUMUMABIts record names the diseaseClinicalTrials.gov
NCT03298867Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical StudyPhase 3832020-03-10Thyroid Eye Disease, Graves' OrbitopathyTEPROTUMUMABIts record names the diseaseClinicalTrials.gov
NCT03938545ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )Phase 2652022-09-22Graves' Ophthalmopathy (GO)BATOCLIMABIts record names the diseaseClinicalTrials.gov
NCT04583735A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye DiseasePhase 4622024-04-26Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye DiseaseTEPROTUMUMABOpen Targets' reading of its recordClinicalTrials.gov
NCT03461211Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension StudyPhase 3512021-07-19Thyroid Eye DiseaseTEPROTUMUMABOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT03122847Glucocorticoids and Bone in Graves' Ophthalmopathy392025-03-19Graves OphthalmopathyMETHYLPREDNISOLONEIts record names the diseaseClinicalTrials.gov
NCT04737330A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)Phase 3282025-01-09Thyroid Eye Disease, Graves OrbitopathySECUKINUMABIts record names the diseaseClinicalTrials.gov
NCT00595335Trial of Rituximab for Graves' OphthalmopathyPhase 2/3252014-06-03Thyroid-associated OphthalmopathyMETHYLPREDNISOLONE, RITUXIMABIts record names the diseaseClinicalTrials.gov
NCT02845336Celecoxib for Thyroid Eye DiseasePhase 272020-07-31Thyroid Eye DiseaseCELECOXIBOpen Targets' reading of its recordClinicalTrials.gov
NCT03922321Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)Phase 272022-01-24Graves' OphthalmopathyBATOCLIMABIts record names the diseaseClinicalTrials.gov

1 to 10 of 52

See all 52 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Safety Population: Teprotumumab vs Safety Population: Placebo: deaths from any cause0 of 430 of 4487NCT01868997Trial comparisons
Safety Population: Teprotumumab vs Safety Population: Placebo: serious adverse events5 of 431 of 4487NCT01868997Trial comparisons
Teprotumumab 20 mg/kg vs Placebo: deaths from any cause0 of 410 of 4283NCT03298867Trial comparisons
Teprotumumab 20 mg/kg vs Placebo: serious adverse events2 of 411 of 4283NCT03298867Trial comparisons
Teprotumumab vs Placebo: deaths from any cause0 of 410 of 2061NCT04583735Trial comparisons
Teprotumumab vs Placebo: serious adverse events1 of 411 of 2061NCT04583735Trial comparisons
Rituximab vs Placebo: serious adverse events2 of 130 of 1225NCT00595335Trial comparisons

Papers from its trials16

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
42117357RESULT1PubMed
36479875RESULT1PubMed
35604323RESULT1PubMed
33574798RESULT1PubMed
31971679RESULT1PubMed
28467880RESULT1PubMed
42837042DERIVED1PubMed
41066062DERIVED2PubMed
37698660DERIVED1PubMed
36173609DERIVED1PubMed

1 to 10 of 16

See all 16 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_1001466

GET https://conductscience.org/api/diseases/v1/EFO_1001466/drugs?page=2

API referenceFor AI assistants